Skip to content

To study the effect of LYFAQUIN™ (Centhaquine citrate) in hypovolemic shock patients.

A prospective, multi-centric, open-labeled, phase-IV study to assess safety and efficacy of LYFAQUIN™ (Centhaquine citrate) as a resuscitative agent for hypovolemic shock to be used as an adjuvant to standard treatment of shock.

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/01/030263
Enrollment
400
Registered
2021-01-05
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: T794- Traumatic shock

Interventions

Intervention1: Lyfaquin (Lyophilized Centhaquin citrate Injection) 1.0 mg/vial: Lyfaquin (Dose: 0.01 mg/kg) + Standard of care: Lyfaquin will be administered intravenously after enrolment in study to

Sponsors

Pharmazz India Private Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Adult males or females aged 18 years or older. 2. Patients with hypovolemic shock admitted to the emergency room or ICU with systolic blood pressure = 90 mmHg at presentation and continue to receive standard shock treatment (endotracheal intubation; fluid resuscitation and vasopressors). Standard of care to be provided to the patients shall be the one used in each hospital setup. 3. Blood Lactate level indicative of hypovolemic shock with lactate level more than 2 mmol/L.

Exclusion criteria

Exclusion criteria: 1. Development of any other terminal illness not associated with hypovolemic shock during study duration. 2. Patient with altered consciousness not due to hypovolemic shock and comatose patient. 3. Known pregnancy. 4. Cardiopulmonary resuscitation (CPR) before enrollment. 5. Presence of a do not resuscitate order. 6. Patient is participating in another interventional study. 7. Patients with systemic diseases which were already present before having trauma, such as: sepsis, cancer, chronic renal failure, liver failure, decompensated heart failure or AIDS. Decision to be made by the investigator.

Design outcomes

Primary

MeasureTime frame
The proportion of patients with adverse events (AEs) and serious adverse events (SAEs)Timepoint: Each patient will be monitored closely throughout his/her hospitalization and will be followed until discharge or day 7 (whichever is earlier) from enrollment

Secondary

MeasureTime frame
Systolic and diastolic blood pressure; Mean through 48 hours and at the time of discharge or day 7.Timepoint: first 48 hours and at the time of discharge or day 7;Base-deficit; Mean through 48 hoursTimepoint: first 48 hours;Time in intensive care unit (ICU)Timepoint: At the time of discharge or day 7;Time on ventilatorTimepoint: at the time of discharge or day 7;Change in blood lactate, Mean through 48 hoursTimepoint: first 48 hours;Urine output during the first 48 hoursTimepoint: first 48 hours;Incidence of mortalityTimepoint: at the time of discharge or day;Multiple Organ Dysfunction Syndrome score (MODS); Mean through day 7 or at the time of dischargeTimepoint: At the time of discharge or day 7;Acute Respiratory Distress Syndrome (ARDS); Mean through day 7 or at the time of dischargeTimepoint: At the time of discharge or day 7;Glasgow Coma Scale (GCS); Mean through day 7 or at the time of dischargeTimepoint: At the time of discharge or day 7

Countries

India

Contacts

Public ContactMr Sunil Gulati

Pharmazz India Pvt. Ltd.

manish.lavhale@pharmazz.com9873847397

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 6, 2026